• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

125I - 4 - 氨基苄基 - 5'-N - 甲基羧酰胺腺苷,一种对大鼠A3腺苷受体具有高亲和力的放射性配体。

125I-4-aminobenzyl-5'-N-methylcarboxamidoadenosine, a high affinity radioligand for the rat A3 adenosine receptor.

作者信息

Olah M E, Gallo-Rodriguez C, Jacobson K A, Stiles G L

机构信息

Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710.

出版信息

Mol Pharmacol. 1994 May;45(5):978-82.

PMID:8190112
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5553074/
Abstract

The rat A3 adenosine receptor (AR) is a recently characterized AR subtype cloned from testis and brain cDNA libraries. N6-2-(4-Amino-3-[125I]iodophenyl)ethyladenosine, a high affinity A1AR agonist, has served as the only radioligand available for study of the A3AR. The relatively low affinity of N6-2-(4-amino-3-[125I] iodophenyl)ethyladenosine for the A3AR and its greater A1AR selectivity necessitate the development of more appropriate radioligands for A3AR analysis. This report characterizes 125I-4-aminobenzyl-5'-N-methylcarboxamidoadenosine (125I-AB-MECA), a high affinity radioligand for the A3AR, in two cell lines that express this AR subtype. Membranes from Chinese hamster ovary (CHO) cells expressing the rat A3AR and from the rat mast cell line RBL-2H3 bound 125I-AB-MECA with Kd values of 1.48 +/- 0.33 nM and 3.61 +/- 0.30 nM, respectively. As determined by 125I-AB-MECA binding, levels of A3AR expression in the A3AR-CHO cell line and RBL-2H3 cells were 3.06 +/- 0.21 pmol/mg and 1.02 +/- 0.13 pmol/mg, respectively. Binding of 125I-AB-MECA was characterized in competition assays. In the A3AR-CHO cell line a potency order of cyclohexyl-5'-N-ethylcarboxamidoadenosine (cyclohexyl-NECA) = benzyl-NECA > (-)-N6-[(R)-phenylisopropyl]adenosine = NECA was observed, and in RBL-2H3 cells (-)-N6-[(R)-phenylisopropyl]adenosine and NECA were equipotent. Xanthine amine congener (XAC) and 8-cyclopentyl-1,3-dipropylxanthine did not significantly inhibit 125I-AB-MECA binding. The parent compound, AB-MECA, dose-dependently inhibited forskolin-stimulated adenylyl cyclase activity in A3AR-CHO cell membranes. 125I-AB-MECA bound to the rat A1AR and canine A2aAR expressed in COS-7 cells with Kd values of 3.42 +/- 0.43 nM and 25.1 +/- 12.6 nM, respectively. This binding was significantly reduced in the presence of 1 microM XAC. In RBL-2H3 cells, XAC had no effect on 125I-AB-MECA affinity and reduced the level of radioligand binding by approximately 5%.

摘要

大鼠A3腺苷受体(AR)是最近从睾丸和脑cDNA文库中克隆得到并鉴定的一种AR亚型。N6-2-(4-氨基-3-[125I]碘苯基)乙基腺苷是一种高亲和力的A1AR激动剂,是目前唯一可用于研究A3AR的放射性配体。N6-2-(4-氨基-3-[125I]碘苯基)乙基腺苷对A3AR的亲和力相对较低,且对A1AR的选择性更高,因此需要开发更合适的放射性配体用于A3AR分析。本报告在两种表达该AR亚型的细胞系中对125I-4-氨基苄基-5'-N-甲基羧酰胺腺苷(125I-AB-MECA)进行了鉴定,它是一种对A3AR具有高亲和力的放射性配体。表达大鼠A3AR的中国仓鼠卵巢(CHO)细胞和大鼠肥大细胞系RBL-2H3的细胞膜与125I-AB-MECA结合,其解离常数(Kd)值分别为1.48±0.33 nM和3.61±0.30 nM。通过125I-AB-MECA结合测定,A3AR-CHO细胞系和RBL-2H3细胞中A3AR的表达水平分别为3.06±0.21 pmol/mg和1.02±0.13 pmol/mg。在竞争结合实验中对125I-AB-MECA的结合特性进行了研究。在A3AR-CHO细胞系中观察到环己基-5'-N-乙基羧酰胺腺苷(环己基-NECA)=苄基-NECA > (-)-N6-[(R)-苯异丙基]腺苷 = NECA的效价顺序,而在RBL-2H3细胞中(-)-N6-[(R)-苯异丙基]腺苷和NECA的效力相当。黄嘌呤胺类似物(XAC)和8-环戊基-1,3-二丙基黄嘌呤对125I-AB-MECA的结合没有显著抑制作用。母体化合物AB-MECA能剂量依赖性地抑制A3AR-CHO细胞膜中福斯可林刺激的腺苷酸环化酶活性。125I-AB-MECA与COS-7细胞中表达的大鼠A1AR和犬A2aAR结合,其Kd值分别为3.42±0.43 nM和25.1±12.6 nM。在1 μM XAC存在的情况下,这种结合显著减少。在RBL-2H3细胞中,XAC对125I-AB-MECA的亲和力没有影响,但使放射性配体的结合水平降低了约5%。

相似文献

1
125I-4-aminobenzyl-5'-N-methylcarboxamidoadenosine, a high affinity radioligand for the rat A3 adenosine receptor.125I - 4 - 氨基苄基 - 5'-N - 甲基羧酰胺腺苷,一种对大鼠A3腺苷受体具有高亲和力的放射性配体。
Mol Pharmacol. 1994 May;45(5):978-82.
2
[125I]4-aminobenzyl-5'-N-methylcarboxamidoadenosine (125I)AB-MECA) labels multiple adenosine receptor subtypes in rat brain.[125I]4-氨基苄基-5'-N-甲基羧酰胺腺苷([125I]AB-MECA)标记大鼠脑中的多种腺苷受体亚型。
Brain Res. 1997 Jan 16;745(1-2):10-20. doi: 10.1016/s0006-8993(96)01120-1.
3
Molecular cloning and characterization of an adenosine receptor: the A3 adenosine receptor.一种腺苷受体的分子克隆与特性分析:A3腺苷受体
Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7432-6. doi: 10.1073/pnas.89.16.7432.
4
Canine mast cell adenosine receptors: cloning and expression of the A3 receptor and evidence that degranulation is mediated by the A2B receptor.犬肥大细胞腺苷受体:A3受体的克隆与表达以及脱颗粒由A2B受体介导的证据
Mol Pharmacol. 1997 Nov;52(5):846-60. doi: 10.1124/mol.52.5.846.
5
A selective agonist affinity label for A3 adenosine receptors.一种A3腺苷受体的选择性激动剂亲和标记物。
Biochem Biophys Res Commun. 1994 Aug 30;203(1):570-6. doi: 10.1006/bbrc.1994.2220.
6
125I-4-(2-[7-amino-2-[2-furyl][1,2,4]triazolo[2,3-a][1,3,5] triazin-5-yl-amino]ethyl)phenol, a high affinity antagonist radioligand selective for the A2a adenosine receptor.125I-4-(2-[7-氨基-2-[2-呋喃基][1,2,4]三唑并[2,3-a][1,3,5]三嗪-5-基氨基]乙基)苯酚,一种对A2a腺苷受体具有高亲和力的选择性拮抗剂放射性配体。
Mol Pharmacol. 1995 Dec;48(6):970-4.
7
Demonstration of both A1 and A2 adenosine receptors in DDT1 MF-2 smooth muscle cells.DDT1 MF-2平滑肌细胞中A1和A2腺苷受体的证实。
Mol Pharmacol. 1990 Feb;37(2):149-56.
8
Cloning, expression and pharmacological characterization of rabbit adenosine A1 and A3 receptors.兔腺苷A1和A3受体的克隆、表达及药理学特性研究
J Pharmacol Exp Ther. 1997 Jan;280(1):122-8.
9
Comparative pharmacology of human adenosine receptor subtypes - characterization of stably transfected receptors in CHO cells.人腺苷受体亚型的比较药理学——CHO细胞中稳定转染受体的特性研究
Naunyn Schmiedebergs Arch Pharmacol. 1998 Jan;357(1):1-9. doi: 10.1007/pl00005131.
10
Molecular cloning and characterization of the human A3 adenosine receptor.人类A3腺苷受体的分子克隆与特性分析
Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):10365-9. doi: 10.1073/pnas.90.21.10365.

引用本文的文献

1
Adenosine A and A Receptors: Distinct Cardioprotection.腺苷A1和A2受体:不同的心脏保护作用。
Drug Dev Res. 2001 Jan-Feb;52(1-2):366-378. doi: 10.1002/ddr.1136.
2
Probing Adenosine and P2 Receptors: Design of Novel Purines and Nonpurines as Selective Ligands.探索腺苷和P2受体:新型嘌呤和非嘌呤作为选择性配体的设计
Drug Dev Res. 2001 Jan-Feb;52(1-2):178-186. doi: 10.1002/ddr.1113.
3
Recent Developments in Selective Agonists and Antagonists Acting at Purine and Pyrimidine Receptors.作用于嘌呤和嘧啶受体的选择性激动剂和拮抗剂的最新进展。

本文引用的文献

1
Adenosine A3 receptors mediate hypotension in the angiotensin II-supported circulation of the pithed rat.腺苷A3受体介导去脑大鼠在血管紧张素II维持的循环中的低血压。
Br J Pharmacol. 1993 May;109(1):3-5. doi: 10.1111/j.1476-5381.1993.tb13522.x.
2
Cloned receptors and cardiovascular responses to adenosine.克隆受体与腺苷对心血管的反应
Cardiovasc Res. 1993 Jan;27(1):62-7. doi: 10.1093/cvr/27.1.62.
3
Molecular cloning and functional expression of a sheep A3 adenosine receptor with widespread tissue distribution.具有广泛组织分布的绵羊A3腺苷受体的分子克隆与功能表达
Drug Dev Res. 1996 Nov-Dec;39(3-4):289-300. doi: 10.1002/(sici)1098-2299(199611/12)39:3/4<289::aid-ddr8>3.0.co;2-n.
4
Species Differences in Ligand Affinity at Central A-Adenosine Receptors.中枢A1-腺苷受体配体亲和力的种属差异。
Drug Dev Res. 1994 Sep;33(1):51-59. doi: 10.1002/ddr.430330109.
5
Species dependence of A adenosine receptor pharmacology and function.A 腺苷受体药理学和功能的种属依赖性。
Purinergic Signal. 2023 Sep;19(3):523-550. doi: 10.1007/s11302-022-09910-1. Epub 2022 Dec 20.
6
Selective A Adenosine Receptor Antagonist Radioligand for Human and Rodent Species.用于人类和啮齿动物的选择性A1腺苷受体拮抗剂放射性配体。
ACS Med Chem Lett. 2022 Mar 2;13(4):623-631. doi: 10.1021/acsmedchemlett.1c00685. eCollection 2022 Apr 14.
7
The Anti-Cancer Effect of A Adenosine Receptor Agonists: A Novel, Targeted Therapy.A腺苷受体激动剂的抗癌作用:一种新型靶向治疗
Immunol Endocr Metab Agents Med Chem. 2007 Aug;7:298-303. doi: 10.2174/187152207781369878.
8
An allosteric inhibitor of bacterial Hsp70 chaperone potentiates antibiotics and mitigates resistance.细菌Hsp70伴侣蛋白的变构抑制剂可增强抗生素效果并减轻耐药性。
Cell Chem Biol. 2022 May 19;29(5):854-869.e9. doi: 10.1016/j.chembiol.2021.11.004. Epub 2021 Nov 23.
9
Subtle Chemical Changes Cross the Boundary between Agonist and Antagonist: New A Adenosine Receptor Homology Models and Structural Network Analysis Can Predict This Boundary.细微的化学变化跨越激动剂和拮抗剂的界限:新的 A 腺苷受体同源模型和结构网络分析可以预测这一界限。
J Med Chem. 2021 Sep 9;64(17):12525-12536. doi: 10.1021/acs.jmedchem.1c00239. Epub 2021 Aug 26.
10
Molecular probes for the human adenosine receptors.用于人类腺苷受体的分子探针。
Purinergic Signal. 2021 Mar;17(1):85-108. doi: 10.1007/s11302-020-09753-8. Epub 2020 Dec 12.
Mol Pharmacol. 1993 Sep;44(3):524-32.
4
The A3 adenosine receptor is the unique adenosine receptor which facilitates release of allergic mediators in mast cells.A3 腺苷受体是唯一能促进肥大细胞释放过敏介质的腺苷受体。
J Biol Chem. 1993 Aug 15;268(23):16887-90.
5
Structure-activity relationships of N6-benzyladenosine-5'-uronamides as A3-selective adenosine agonists.N6-苄基腺苷-5'-脲酰胺作为A3选择性腺苷激动剂的构效关系
J Med Chem. 1994 Mar 4;37(5):636-46. doi: 10.1021/jm00031a014.
6
Validation and statistical analysis of a computer modeling method for quantitative analysis of radioligand binding data for mixtures of pharmacological receptor subtypes.一种用于药理学受体亚型混合物放射性配体结合数据定量分析的计算机建模方法的验证与统计分析
Mol Pharmacol. 1982 Jan;21(1):5-16.
7
A highly sensitive adenylate cyclase assay.一种高灵敏度的腺苷酸环化酶检测方法。
Anal Biochem. 1974 Apr;58(2):541-8. doi: 10.1016/0003-2697(74)90222-x.
8
Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.抑制常数(K1)与导致酶促反应50%抑制率(I50)的抑制剂浓度之间的关系。
Biochem Pharmacol. 1973 Dec 1;22(23):3099-108. doi: 10.1016/0006-2952(73)90196-2.
9
Use of eukaryotic expression technology in the functional analysis of cloned genes.真核表达技术在克隆基因功能分析中的应用。
Methods Enzymol. 1987;152:684-704. doi: 10.1016/0076-6879(87)52074-2.
10
N6-substituted N-alkyladenosine-5'-uronamides: bifunctional ligands having recognition groups for A1 and A2 adenosine receptors.N6-取代的N-烷基腺苷-5'-脲酰胺:对A1和A2腺苷受体具有识别基团的双功能配体。
J Med Chem. 1986 Sep;29(9):1683-9. doi: 10.1021/jm00159a020.